List view / Grid view

News

 

16 June 2011 Bristol-Myers Squibb logo

FDA approves NULOJIX® (belatacept)

16 June 2011 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

Send this to a friend